T2-signal intensity, SSTR expression, and somatostatin analogs efficacy predict response to pasireotide in acromegaly

in European Journal of Endocrinology

Correspondence should be addressed to E C Coopmans; Email: e.coopmans@erasmusmc.nl
Restricted access

Objective

T2-signal intensity and somatostatin (SST) receptor expression are recognized predictors of therapy response in acromegaly. We investigated the relationship between these predictors and the hormonal and tumoral responses to long-acting pasireotide (PAS-LAR) therapy, which were also compared with responsiveness to first-generation somatostatin receptor ligands (SRLs).

Design

The PAPE study is a cohort study.

Methods

We included 45 acromegaly patients initially receiving SRLs, followed by combination therapy with pegvisomant, and finally PAS-LAR. We assessed tumor volume reduction (≥25% from baseline), IGF-1 levels (expressed as the upper limit of normal), and T2-weighted MRI signal and SST receptor expression of the adenoma.

Results

Patients with significant tumor shrinkage during PAS-LAR showed higher IGF-1 levels during PAS-LAR (mean (S.D.): 1.36 (0.53) vs 0.93 (0.43), P = 0.020), less IGF-1 reduction after first-generation SRLs (mean (S.D.): 0.55 (0.71) vs 1.25 (1.07), P = 0.028), and lower SST2 receptor expression (median (IQR): 2.0 (1.0–6.0) vs 12.0 (7.5–12.0), P = 0.040). Overall, T2-signal intensity ratio was increased compared with baseline (mean (S.D.): 1.39 (0.56) vs 1.25 (0.52), P = 0.017) and a higher T2-signal was associated with lower IGF-1 levels during PAS-LAR (β: −0.29, 95% CI: −0.56 to −0.01, P = 0.045). A subset of PAS-LAR treated patients with increased T2-signal intensity achieved greater reduction of IGF-1 (mean (S.D.): 0.80 (0.60) vs 0.45 (0.39), P = 0.016).

Conclusions

Patients unresponsive to SRLs with a lower SST2 receptor expression are more prone to achieve tumor shrinkage during PAS-LAR. Surprisingly, tumor shrinkage is not accompanied by a biochemical response, which is accompanied with a higher T2-signal intensity.

 

     European Society of Endocrinology

Sept 2018 onwards Past Year Past 30 Days
Abstract Views 331 331 331
Full Text Views 51 51 51
PDF Downloads 38 38 38
  • 1

    MelmedS. Acromegaly pathogenesis and treatment. Journal of Clinical Investigation 2009 119 31893202. (https://doi.org/10.1172/JCI39375)

    • Search Google Scholar
    • Export Citation
  • 2

    MelmedSBronsteinMDChansonPKlibanskiACasanuevaFFWassJAHStrasburgerCJLugerAClemmonsDRGiustinaA. A Consensus Statement on acromegaly therapeutic outcomes. Nature Reviews: Endocrinology 2018 14 552561. (https://doi.org/10.1038/s41574-018-0058-5)

    • Search Google Scholar
    • Export Citation
  • 3

    Signifor LAR (package insert). East Hanover: Novartis Pharmaceuticals Corporation2014.

  • 4

    Signifor LAR (summary of product characteristics). Basel: Novartis Pharma AG2014.

  • 5

    ColaoABronsteinMDFredaPGuFShenCCGadelhaMFleseriuMvan der LelyAJFarrallAJHermosillo ResendizK et al. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. Journal of Clinical Endocrinology and Metabolism 2014 99 791799. (https://doi.org/10.1210/jc.2013-2480)

    • Search Google Scholar
    • Export Citation
  • 6

    GadelhaMRBronsteinMDBrueTCoculescuMFleseriuMGuitelmanMProninVRaverotGShimonILievreKK et al. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet: Diabetes and Endocrinology 2014 2 875884. (https://doi.org/10.1016/S2213-8587(14)70169-X)

    • Search Google Scholar
    • Export Citation
  • 7

    MuhammadAvan der LelyAJDelhantyPJDDallengaAHGHaitsmaIKJanssenJNeggersS. Efficacy and safety of switching to pasireotide in acromegaly patients controlled with pegvisomant and first-generation somatostatin analogues (PAPE study). Journal of Clinical Endocrinology and Metabolism 2017 103 586595. (https://doi.org/10.1210/jc.2017-02017)

    • Search Google Scholar
    • Export Citation
  • 8

    MuhammadACoopmansECDelhantyPJDDallengaAHGHaitsmaIKJanssenJAMJLVan der LelyAJNeggersSJCMM. Efficacy and safety of switching to pasireotide in acromegaly patients controlled with pegvisomant and somatostatin analogues: PAPE extension study. European Journal of Endocrinology 2018 179 269277. (https://doi.org/10.1530/EJE-18-0353)

    • Search Google Scholar
    • Export Citation
  • 9

    PotoracIPetrossiansPDalyAFAlexopoulouOBorotSSahnoun-FathallahMCastinettiFDevuystFJaffrain-ReaMLBrietC et al. T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly. Endocrine-Related Cancer 2016 23 871881. (https://doi.org/10.1530/ERC-16-0356)

    • Search Google Scholar
    • Export Citation
  • 10

    PotoracIPetrossiansPDalyAFSchilloFBen SlamaCNagiSSahnounMBrueTGirardNChansonP et al. Pituitary MRI characteristics in 297 acromegaly patients based on T2-weighted sequences. Endocrine-Related Cancer 2015 22 169177. (https://doi.org/10.1530/ERC-14-0305)

    • Search Google Scholar
    • Export Citation
  • 11

    HeckARingstadGFougnerSLCasar-BorotaONomeTRamm-PettersenJBollerslevJ. Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly. Clinical Endocrinology 2012 77 7278. (https://doi.org/10.1111/j.1365-2265.2011.04286.x)

    • Search Google Scholar
    • Export Citation
  • 12

    HagiwaraAInoueYWakasaKHabaTTashiroTMiyamotoT. Comparison of growth hormone-producing and non-growth hormone-producing pituitary adenomas: imaging characteristics and pathologic correlation. Radiology 2003 228 533538. (https://doi.org/10.1148/radiol.2282020695)

    • Search Google Scholar
    • Export Citation
  • 13

    ShenMZhangQLiuWWangMZhuJMaZHeWLiSShouXLiY et al. Predictive value of T2 relative signal intensity for response to somatostatin analogs in newly diagnosed acromegaly. Neuroradiology 2016 58 10571065. (https://doi.org/10.1007/s00234-016-1728-4)

    • Search Google Scholar
    • Export Citation
  • 14

    BonnevilleFRiviereLDPetersennSBevanJHouchardASertCCaronPJ & PRIMARYS Study group. MRI T2 signal intensity and tumor response in patients with GH-secreting pituitary macroadenoma: PRIMARYS post-hoc analysis. European Journal of Endocrinology 2019 180 155164. (https://doi.org/10.1530/EJE-18-0254)

    • Search Google Scholar
    • Export Citation
  • 15

    GattoFFeeldersRAvan der PasRKrosJMWaaijersMSprij-MooijDNeggersSJvan der LelijAJMinutoFLambertsSW et al. Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly. Journal of Clinical Endocrinology and Metabolism 2013 98 E66E71. (https://doi.org/10.1210/jc.2012-2609)

    • Search Google Scholar
    • Export Citation
  • 16

    Casar-BorotaOHeckASchulzSNeslandJMRamm-PettersenJLekvaTAlafuzoffIBollerslevJ. Expression of SSTR2a, but not of SSTRs 1, 3, or 5 in somatotroph adenomas assessed by monoclonal antibodies was reduced by octreotide and correlated with the acute and long-term effects of octreotide. Journal of Clinical Endocrinology and Metabolism 2013 98 E1730E1739. (https://doi.org/10.1210/jc.2013-2145)

    • Search Google Scholar
    • Export Citation
  • 17

    SchmidHA. Pasireotide (SOM230): development, mechanism of action and potential applications. Molecular and Cellular Endocrinology 2008 286 6974. (https://doi.org/10.1016/j.mce.2007.09.006)

    • Search Google Scholar
    • Export Citation
  • 18

    Ibanez-CostaARivero-CortesEVazquez-BorregoMCGaheteMDJimenez-ReinaLVenegas-MorenoEde la RivaAArraezGonzalez-MoleroISchmidHA et al. Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro. Journal of Endocrinology 2016 231 135145. (https://doi.org/10.1530/JOE-16-0332)

    • Search Google Scholar
    • Export Citation
  • 19

    GattoFFeeldersRAFranckSEvan KoetsveldPMDoganFKrosJMNeggersSJCMMvan der LelyAJLambertsSWJFeroneD et al. In vitro head-to-head comparison Between octreotide and pasireotide in GH-secreting pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 2017 102 20092018. (https://doi.org/10.1210/jc.2017-00135)

    • Search Google Scholar
    • Export Citation
  • 20

    ManolopoulouJAlamiYPetersennSSchopohlJWuZStrasburgerCJBidlingmaierM. Automated 22-kD growth hormone–specific assay without interference from pegvisomant. Clinical Chemistry 2012 58 14461456. (https://doi.org/10.1373/clinchem.2012.188128)

    • Search Google Scholar
    • Export Citation
  • 21

    BidlingmaierMFriedrichNEmenyRTSprangerJWolthersODRoswallJKornerAObermayer-PietschBHubenerCDahlgrenJ et al. Reference intervals for insulin-like growth factor-1 (IGF-I) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations. Journal of Clinical Endocrinology and Metabolism 2014 99 17121721. (https://doi.org/10.1210/jc.2013-3059)

    • Search Google Scholar
    • Export Citation
  • 22

    LundinPPedersenF. Volume of pituitary macroadenomas: assessment by MRI. Journal of Computer Assisted Tomography 1992 16 519528. (https://doi.org/10.1097/00004728-199207000-00004)

    • Search Google Scholar
    • Export Citation
  • 23

    MuhammadACoopmansECGattoFFranckSEJanssenJAMJLvan der LelyAJHoflandLJNeggersSJCMM. Pasireotide responsiveness in acromegaly is mainly driven by somatostatin receptor subtype 2 expression. Journal of Clinical Endocrinology and Metabolism 2019 104 915924. (https://doi.org/10.1210/jc.2018-01524)

    • Search Google Scholar
    • Export Citation
  • 24

    RemmeleWStegnerHE. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Der Pathologe 1987 8 138140.

    • Search Google Scholar
    • Export Citation
  • 25

    NeggersSJFranckSEde RooijFWDallengaAHPoublonRMFeeldersRAJanssenJABuchfelderMHoflandLJJorgensenJO et al. Long-term efficacy and safety of pegvisomant in combination with long-acting somatostatin analogs in acromegaly. Journal of Clinical Endocrinology and Metabolism 2014 99 36443652. (https://doi.org/10.1210/jc.2014-2032)

    • Search Google Scholar
    • Export Citation
  • 26

    CoopmansECvan der LelyAJSchneidersJJNeggersSJCMM. Potential antitumour activity of pasireotide on pituitary tumours in acromegaly. Lancet: Diabetes and Endocrinology 2019 7 425426. (https://doi.org/10.1016/S2213-8587(19)30113-5)

    • Search Google Scholar
    • Export Citation
  • 27

    BronsteinMDFleseriuMNeggersSColaoASheppardMGuFShenCCGadelhaMFarrallAJHermosillo ResendizK et al. Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, phase III study. BMC Endocrine Disorders 2016 16 16. (https://doi.org/10.1186/s12902-016-0096-8)

    • Search Google Scholar
    • Export Citation
  • 28

    BesserGMBurmanPDalyAF. Predictors and rates of treatment-resistant tumor growth in acromegaly. European Journal of Endocrinology 2005 153 187193. (https://doi.org/10.1530/eje.1.01968)

    • Search Google Scholar
    • Export Citation
  • 29

    HoflandLJvan der HoekJvan KoetsveldPMde HerderWWWaaijersMSprij-MooijDBrunsCWeckbeckerGFeeldersRvan der LelyAJ et al. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. Journal of Clinical Endocrinology and Metabolism 2004 89 15771585. (https://doi.org/10.1210/jc.2003-031344)

    • Search Google Scholar
    • Export Citation
  • 30

    JaquetPSaveanuAGunzGFinaFZamoraAJGrinoMCullerMDMoreauJPEnjalbertAOuafikLH. Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes. Journal of Clinical Endocrinology and Metabolism 2000 85 781792. (https://doi.org/10.1210/jcem.85.2.6338)

    • Search Google Scholar
    • Export Citation
  • 31

    PlockingerUAlbrechtSMawrinCSaegerWBuchfelderMPetersennSSchulzS. Selective loss of somatostatin receptor 2 in octreotide-resistant growth hormone-secreting adenomas. Journal of Clinical Endocrinology and Metabolism 2008 93 12031210. (https://doi.org/10.1210/jc.2007-1986)

    • Search Google Scholar
    • Export Citation
  • 32

    BarkanALBeitinsIZKelchRP. Plasma insulin-like growth factor-I/somatomedin-C in acromegaly: correlation with the degree of growth hormone hypersecretion. Journal of Clinical Endocrinology and Metabolism 1988 67 6973. (https://doi.org/10.1210/jcem-67-1-69)

    • Search Google Scholar
    • Export Citation
  • 33

    TrainerPJDrakeWMKatznelsonLFredaPUHerman-BonertVvan der LelyAJDimarakiEVStewartPMFriendKEVanceML et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. New England Journal of Medicine 2000 342 11711177. (https://doi.org/10.1056/NEJM200004203421604)

    • Search Google Scholar
    • Export Citation
  • 34

    HeckAEmblemKECasar-BorotaORingstadGBollerslevJ. MRI T2 characteristics in somatotroph adenomas following somatostatin analog treatment in acromegaly. Endocrine 2016 53 327330. (https://doi.org/10.1007/s12020-015-0816-2)

    • Search Google Scholar
    • Export Citation